>
Many medical, technological, and economic factors impact heart tumor market trends in complex ways. In the healthcare business, the heart tumor market deals with a range of heart tumors, which may be both a problem and an opportunity.
The market is affected by heart tumors' prevalence. Increased awareness and better testing technologies have helped discover the condition early, boosting market growth. More consumers and clinicians are interested in cardiac tumor detection and treatment techniques as they learn more about them.
Modern diagnostic technologies have revolutionized cardiac tumor detection and classification. Market growth is driven by new imaging modalities like MRI and CT scans, which help provide accurate diagnosis. In the cardiac tumor market, accurate and non-invasive diagnostics is popular.
The treatment of cardiac tumors has evolved significantly. Open-heart and minimally invasive surgery are major components of the therapeutic regimen. Due to pharmacological and customized medicine advances, treatment options are evolving, making the market active.
Research and development will shape the heart tumor market. Pharmaceutical companies, research schools, and healthcare organizations collaborate to innovate. Investing in immunotherapy research demonstrates you desire to address market gaps.
Location and patient type effect heart growth rates and market performance. Due to healthcare facilities, advanced medical technologies, and societal aspects like age and genetics, the market is diverse.
The political atmosphere affects markets. How severe drug approval and instrument testing standards are affects market growth. Treatment safety and efficacy depend on regulatory groupings. They influence market participants' competitive landscape.
Big companies compete in the heart tumor market. Famous medicine corporations, medical gadget businesses, and newcomers compete. To increase their market position, corporations collaborate, merge, or purchase other enterprises.
Patient advocacy and support organizations are interesting in the heart tumor industry. These organizations are crucial for spreading information, supporting patients and their families, and funding research. Their influence extends beyond medicine and helps us comprehend the industry.
The heart tumor market may evolve further. Problems including tailoring medications, eliminating location-based healthcare access, and streamlining regulations will change the industry. The heart tumor market changes, therefore everyone must collaborate, invest in research, and be patient-centered.
Heart Tumor Market Size was valued at USD 0.95 Billion in 2023. The Global Heart Tumor industry is projected to grow from USD 1.02 Billion in 2024 to USD 1.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.04% during the forecast period (2024 - 2032).
An abnormal growth of heart tissue is referred to as a cardiac tumor, which can be either cancerous (malignant) or non-cancerous. Cardiac Tumor can also be categorized as primary (coming from the heart itself) or secondary. Primary cardiac tumor is extremely uncommon, affecting just around 1 in 3000 people. The majority of initial heart tumor—75%—are benign. Secondary cardiac tumor most frequently develops in people with lung cancer, breast cancer, melanoma, renal cell carcinoma, or lymphoma and are 20–30 times more likely than primary cardiac tumor. The market is driven by factors like the growing prevalence of cardiac tumors, increasing number of cancer research and funding, and the rising number of strategic initiatives. Nevertheless, increasing initiatives by public and private organizations to drive awareness regarding heart tumor is anticipated to create lucrative opportunities for the players operating in the heart tumor market. However, lack of awareness among people, and lack of skilled radiologists could hamper the growth of the heart tumor market.
COVID-19 Analysis
The COVID-19 pandemic had negatively impacted the heart tumor market in the initial phase of the pandemic, causing a reduction in productivity, shutdown/reduced activity in manufacturing plants, and disruption in the supply chain.
However, the COVID-19 pandemic has moderately disrupted the production and revenue of many companies. Most key players have their manufacturing units in different regions which were highly affected by this pandemic due to restriction laid down by the authorities to curb virus transmission. Key companies such as Koninklijke Philips N.V. (Netherlands), Siemens AG (Germany), Hitachi, Ltd. (Japan), GE Healthcare (US) and others are highly dependent on several regional markets for revenue generation, but the pandemic and slowdown globally had negatively affected the company’s growth in these regions in 2020. For instance, the shortage of Iodinated Contrast Media (ICM) due to a General Electric manufacturing shutdown in Shanghai, China owing to COVID-19 lockdown in April 2022, has caused significant effects on radiology practices globally.
Heart Tumor Market Dynamics
Market Drivers
Market Restraints
Market Opportunities
Value Chain Analysis
The value chain analysis for the heart tumor market comprises four major components that start with the research and product development (R&D), followed by the manufacturing of the products, distribution & sales, and ends with post-sales monitoring.
In the research and product development stage, new techniques and research are undertaken to develop new products, and to make the existing products better and unique. In manufacturing stage, the product strategies are ready, and the manufacturing process of the product starts. In distribution & sales, the company's marketing and sales strategies play a crucial role in understanding the characteristics of the industry in which one is competing. Many players sponsor seminars, knowledge sessions, and other activities, including checking for potential interactions and providing advice, each of which is expected to guarantee the end user gets the awareness, full advantage, and value from the products accordingly. Furthermore, in the post-marketing monitoring stage, it begins with a periodic safety update report of the drug or device to be submitted to the FDA after the drug or device comes into the market.
Segment Overview
Tumor Type
Primary Heart Cardiac (PCT) is a deadly and uncommon condition. Primary tumors are classified into malignant and benign. For instance, according to a SpringerLink article from October 2020, 10% are malignant tumors that are pathologically labelled as sarcomas, and about 90% are benign tumors. Moreover, the major benign tumors that have high chances of becoming malignant are myxomas, rhabdomyoma, and others, including fibromas, lipomas, hemangiomas, papillary fibroelastomas, cystic tumors of the atrioventricular node, and paragangliomas. Soft tissue sarcomas are the common PCTs.
The common secondary cardiac tumor is epicardial compared to myocardial and endocardial, and only 10% are symptomatic secondary tumors. For instance, in June 2020, a ScienceDirect article on cardiac tumors reported that SCTs are 20 to 40 times common and frequent than Primary Cardiac Tumors (PCTs). At autopsy, approximately 12% of patients are diagnosed with SCTs, with the majority remaining clinically silent.
By Diagnosis & Treatment
The heart tumor can be diagnosed by CT scans, Magnetic Resonance Imaging (MRI) scans, nuclear imaging, echocardiography, and others. The cardiac CT scan is used to identify narrowed or blocked arteries. Moreover, cardiac MRI provides multiplanar information related to the cardiac masses, including surrounding structures. It is also beneficial due to the appropriate identification of benign and malignant tumors as well as in providing psuedomass information. In addition, other diagnosis methods includes for heart tumor is Electrocardiogram (ECG), electrophysiology tests and cardiac biopsy.
The treatment segment includes surgery, chemotherapy, radiotherapy, and others. Surgical procedures include surgical excision, transplantation, and catheterization. Additionally, Surgery removes the growth of cancerous tumors or cancerous tumors. For instance, according to the Journal of Cardiothoracic Surgery published in April 2019, it is effective, durable, and safe for primary benign cardiac tumors. A study conducted in the Journal of Cardiothoracic Surgery from 2008 to 2018 showed that 19 men and 31 women were enrolled with left atrium (80.0%), right atrium (16.0%), right ventricle (2.0%), and left ventricle (2.0%) from age 55 to 17.5 years.
Regional Analysis
GLOBAL HEART TUMOR MARKET SHARE (%), BY Region, 2021Source: MRFR analysis
The North America held the largest market share of 40.72% based on region and is anticipated to dominate the overall heart tumor market during the forecast period.
North America
The North America comprising the US and Canada— North America held the largest market share in 2021. This is due to factors such as the major use of cardiac biopsies and high prevalence of PCTs in the region. According to a research article published in the International Journal of Surgery (IJS) by Mohamed Rahouma et al, in March 2020, a meta-analysis on cardiac tumors and the utilization of heart transplantation was performed. Primary Malignant Cardiac Tumors (PMCTs) are a minority of Primary Cardiac Tumors (PCTs) and are more prevalent in North America and Europe than in other regions, which is supplementing demand for the heart tumor market
north america HEART TUMOR MARKET SHARE (%), BY country, 2021Source: MRFR analysis
Asia-pacific
Asia-Pacific is anticipated to register the highest CAGR of 8.06% over the forecast period. This is due to factors like presence off several key companies and they are actively investing and expanding through acquisitions, mergers, expansion, and product launches in the region. According to an article published in June 2018 by the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), cardiac rhabdomyoma tumor is the most common cardiac tumor in the fetus in Japan.
Competitive Landscape
The global heart tumor market is extremely competitive, with players competing, partnering, and investing heavily in R&D to gain a significant market share. The market is moderately fragmented with rising competition, product launches, increasing collaborative partnerships, and other strategic decisions to achieve operational efficiency. Market Research Future’s analysis revealed that market players have adopted different strategies and innovative research and development techniques to expand their business and secure their position in the global preclinical heart tumor market. In recent years, strategic movements by major players included approvals, which have been used as market penetration strategies and a means to reduce competition
Moreover, the major players have adopted strategies such as acquisitions, expansion, and collaborations to augment their position in the market. For instance, in April, 2022 Shimadzu Corporation (Japan) launched the Trinias Angiography system to improve medical device visibility. It contains extra customization capabilities that allow for the establishment of a basic, user-friendly workspace that allows for successful operation in a medical setting
List of companies with HQ
Recent Developments
Report Overview
The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.
Study Objectives
Market Segmentation:
Global Heart Tumor Market, Tumor Type
Global Heart Tumor Market, By Diagnosis & Treatment
Global Heart Tumor Market, By Region
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)